Skip to main content

Table 1 Descriptive statistics of the total group of patients who underwent RRSO (n = 471)

From: The lack of clinical value of peritoneal washing cytology in high risk patients undergoing risk-reducing salpingo-oophorectomy: a retrospective study and review

 

Number

Percentage

Range

Age (median, year)

48

%

33–78

Mutations

   

-BRCA1

288

61.1

 

-BRCA2

126

26.8

 

-BRCA1 and BRCA2

2

0.4

 

-HBOC

55

11.7

 

CA-125 preoperative (n)

466

  

-median (U/ml)

14.0

 

4.0–93.0

-elevated CA125 (>35 U/ml) (n)

10

2.1

 

Surgical technique (n)

471

  

-laparoscopy

430

91.3

 

-laparotomy

37

7.9

 

-vaginal

3

0.6

 

-combined with supravaginal uterus extirpation

1

0.2

 

Documented complications (n)

444

94.3

 

-no complications during surgery and/or postoperatively

416

93.7

 

-complications

28

5.9

 

 -converted to laparotomy because of adhesions

10

  

 -hematoma

10

  

 -iatrogenic injury (intestine/ureter)

3

  

 -incomplete removal of the ovaries

1

  

 -not possible to remove ovaries because of adhesions

1

  

 -other

3

  

Menopausal status (n)

447

  

-postmenopausal

187

41.8

 

 -because of hormonal breast cancer treatment

32

17.1

 

 -because of previous ovariectomy

8

4.3

 

-premenopausal

241

53.9

 

-perimenopausal

19

4.3

 

 -because of hormonal breast cancer treatment

10

52.6

 

HRT in premenopausal women (n)

217

  

 -postoperative usage of HRT

97

45.3

 

Follow up (median, mo) (n = 375)

55.8

 

0.6–169.0

-deceased in FU

19

5.1

 

 -age (median, year)

55.5

 

43.1–72.0

-development of breast cancer in FU

57

12.1

 

-development of PPC in FU

1

0.2

 

-development of other malignancy

22

4.7

 

Previous breast cancer (n)

195

41.4

 

-age first breast cancer (median, year)

41.0

 

24.7–64.0

Cytology

   

PWC sample not available

191

40.6

 

PWC sample available

280

59.4

 

-PWC analyzable

257

91.8

 

 -PWC malignant

4

1.6

 

 -PWC atypical

1

0.4

 

Ascites sample reported

21

4.5

 

-Ascites sample available for analysis

13

61.9

 

 -ascites malignant

0

0

 

 -ascites atypical

0

0

 

Histology RRSO specimen

   

Ovarian (n)

469

  

-benign

399

85.1

 

-primary serous adenocarcinoma

4

0.9

 

-granulosa cell tumor

1

0.2

 

-borderline tumor

1

0.2

 

-stromal hyperplasia

2

0.4

 

-mature cystic teratoma (benign)

4

0.9

 

-cyst (serous/mucinous/simple/endometriosis/Theca lutein/corpus luteum)

43

9.2

 

-cystadenoma/cystadenofibroma

15

3.2

 

Fallopian tube (n)

470

  

-benign

433

92.1

 

-adenocarcinoma

5

0.6

 

-serous large cell carcinoma

1

0.2

 

-benign mesothelial hyperplasia

1

0.2

 

-epithelial dysplasia

1

0.2

 

-cystadenoma/cystadenofibroma

9

1.9

 

-endometriosis

7

1.5

 

-endosalpingiosis

13

2.8